Crystal Submits Clinical Phase 1 Trial Completion Report for Neuropathic Pain and Anti-inflammatory Combination Therapy
[Asia Economy Reporter Oh Ju-yeon] Crystal announced on the 12th that it has submitted the clinical phase 1 trial completion report for the neuropathic pain anti-inflammatory combination drug CG-651 (Polmacoxib+Pregabalin). The company stated, "The global analgesics market is estimated to be worth over 55 trillion KRW, and it is expected to grow at an annual rate of 4% due to population aging and continuous new product launches."
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- "Was This Delicious Treat Enjoyed Only by Koreans?"... The K-Dessert Captivating Japan
- Despite Captivating the Nation for Over a Month... "Timmy" the Whale Ultimately Found Dead
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
However, the company noted that the probability of the clinical trial drug receiving final approval as a pharmaceutical product is statistically about 10%, and advised that investors should carefully consider the disclosed investment risks through timely disclosures and business reports before investing.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
